Investigational drug · Phase 3
AZD0120
Also called: GC012F
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
12
Any phase or sponsor naming "AZD0120"
First trial start
2023
Jul 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD0120", any sponsor or status.
Conditions studied
As listed on its trial records.
- Newly Diagnosed Multiple Myeloma (NDMM)
- Relapsed AL Amyloidosis
- Refractory AL Amyloidosis
- Light Chain Amyloidosis
- Amyloidosis
- Relapsed/Refractory Multiple Myeloma
- Refractory Systemic Lupus Erythematosus
- Lupus Erythematosus, Systemic
- Systemic Sclerosis
- Idiopathic Inflammatory Myopathies
Approved drugs for the same conditions: Multiple myeloma · Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD0120" as an intervention, largest first.
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07735637 · 750 participants (planned) · Start Sep 24, 2026 · Primary completion Nov 2, 2028
Drug: AZD0120; Cyclophosphamide and 3 more · For: Newly Diagnosed Multiple Myeloma (NDMM)
Sites: Gilbert, Arizona; Goodyear, Arizona; Phoenix, Arizona · 114 sites in all
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07764978 · 750 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 11, 2029
Drug: AZD0120; Daratumumab and 6 more · For: Newly Diagnosed Multiple Myeloma
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 124 sites in all
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07391657 · 508 participants (planned) · Start Feb 23, 2026 · Primary completion Jun 14, 2028
Drug: AZD0120; Daratumumab and 4 more · For: Relapsed Refractory Multiple Myeloma
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 143 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05850234 · 232 participants (planned) · Start Jul 20, 2023 · Primary completion Oct 1, 2027
Drug: AZD0120 · For: Relapsed/Refractory Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 36 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06897930 · 150 participants (planned) · Start Apr 21, 2025 · Primary completion May 1, 2029
Drug: AZD0120; Cyclophosphamide and 1 more · For: Lupus Erythematosus, Systemic
Sites: San Francisco, California; Stanford, California; Tampa, Florida · 20 sites in all
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
NCT07081646 · 91 participants (planned) · Start Aug 18, 2025 · Primary completion Aug 15, 2029
Drug: AZD0120 · For: Relapsed AL Amyloidosis; Refractory AL Amyloidosis; Light Chain Amyloidosis and 1 more
Sites: Phoenix, Arizona; San Francisco, California; Tampa, Florida · 18 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07073547 · 40 participants (planned) · Start Jul 31, 2025 · Primary completion May 26, 2028
Drug: AZD0120 · For: Multiple Myeloma
Sites: Phoenix, Arizona; Duarte, California; Denver, Colorado · 13 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07295847 · 27 participants (planned) · Start Jan 9, 2026 · Primary completion Feb 22, 2028
Drug: AZD0120; SOC · For: Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Rheumatoid Arthritis
Sites: Tucson, Arizona; Duarte, California; Stanford, California · 27 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07224373 · 24 participants (planned) · Start Dec 9, 2025 · Primary completion Dec 12, 2028
Drug: AZD0120 - Regimen 1; AZD0120 - Regimen 2 · For: Multiple Sclerosis
Sites: Tucson, Arizona; Aurora, Colorado; Washington D.C., District of Columbia · 20 sites in all
Saurabh DahiyaAcademic, hospital or other
NCT07790575 · 16 participants (planned) · Start Sep 2026 · Primary completion Jul 2041
Drug: AZD0120; Bendamustin · For: Cytopenia
Sites: Stanford, California
Newest research
PubMed records naming it or its code names, newest first.
- BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study.
Liu J, Fan X, Peng L, et al. · Blood Adv 2026
- Advances in CD19-targeting CAR-T cell therapies for multiple myeloma.
Steinhardt MJ, Einsele H, Waldschmidt JM · Expert Opin Biol Ther 2025
- B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.
Qiang W, Lu J, Jia Y, et al. · JAMA Oncol 2024
- Current state and next-generation CAR-T cells in multiple myeloma.
Manier S, Ingegnere T, Escure G, et al. · Blood Rev 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.